<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845130</url>
  </required_header>
  <id_info>
    <org_study_id>11119</org_study_id>
    <nct_id>NCT00845130</nct_id>
  </id_info>
  <brief_title>Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes</brief_title>
  <official_title>Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>In-Young Choi, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress has been implicated in the development and complications of diabetes.
      Hyperglycemia and insulin resistance or insufficiency in diabetes can cause oxidative stress
      by excessive reactive oxygen species and can increase damage and alter antioxidant status in
      nerve cells. Antioxidant defense mechanisms protect against damage or restore oxidative
      damage. Glutathione, a powerful antioxidant plays a key role in the first line of antioxidant
      defense and seems to be a sensitive indicator of oxidative stress in various diseases such as
      diabetes. Glutathione functions in the regeneration of vitamin C which is another crucial
      antioxidant. Both hyperglycemia and insulin insufficiency inhibit uptake of vitamin C. The
      brain contains measurable amounts of glutathione that contribute to the antioxidant pool in
      the brain and guards against disease processes that are caused by oxidative stress. Since the
      brain is the most highly oxidative organ in the body and highly susceptible to oxidative
      stress, with increasing impact on diabetes, biomarkers of oxidative stress in the brain
      through the use of novel magnetic resonance imaging techniques for glutathione and vitamin C
      will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The brain contains measurable amounts of glutathione that contribute to the antioxidant pool
      in the brain and guards against disease processes that are caused by oxidative stress. Since
      the brain is the most highly oxidative organ in the body and highly susceptible to oxidative
      stress, with increasing impact on diabetes, biomarkers of oxidative stress in the brain
      through the use of novel magnetic resonance imaging techniques for glutathione and vitamin C
      will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Vitamin C in Type 2 Diabetic Patients.</measure>
    <time_frame>Pre-Vitamin C infusion</time_frame>
    <description>Concentrations of vitamin C were measured in the brains of type 2 Diabetic patients and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier</measure>
    <time_frame>2 hour post infusion</time_frame>
    <description>Concentrations of vitamin C after IV infusion of Vitamin C were measured in the brains of patients with type 2 diabetes and healthy controls to examine whether the concentrations are different between two groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Diabetic Type II Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ascorbic acid (Vitamin C)</intervention_name>
    <description>ascorbic acid IV 1 g/kg</description>
    <arm_group_label>Diabetic Type II Subjects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30-55 years of age

          -  Diabetic being treated with diet and any of the following: insulin, or other diabetic
             specific drug such as metformin, sulfonylurea or sitagliptin.

          -  Healthy subjects age and gender matched to diabetes patient

        Exclusion Criteria:

          -  Use of any anti-inflammatory or antioxidant medications other than small daily doses
             of Aspirin (ASA:325 mg) and a daily multivitamin

          -  Co-existing chronic inflammatory conditions such as Crohn's disease, rheumatoid
             arthritis, chronic or acute infections

          -  Any concurrent neurological disease except for mild diabetic autonomic or peripheral
             neuropathy

          -  Postmeal C peptide &gt; 0.3 mg/dl

          -  Normal healthy subjects who have any abnormal inflammatory marker, hyperlipidemia, or
             concurrent disease

          -  Diseases associated with abnormal glutathione metabolism

          -  Elevated serum creatinine levels, abnormal complete blood count (CBC), abnormal liver
             function tests or elevated serum homocysteine

          -  Morbid obesity

          -  History of hypoglycemic unawareness

          -  Pregnant women and women who are breastfeeding

          -  Patients with poor venous access

          -  Smokers

          -  Subject who consumes an excess of alcohol or abuses drugs

          -  History or or presence of bleeding disorder or use of anticoagulant drug

          -  History of oxalate renal calculi
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Young Choi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Un iversity of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <results_first_submitted>June 9, 2016</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2016</results_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>In-Young Choi, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>MR imaging</keyword>
  <keyword>Vitamin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No, there is not a plan to share individual data.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All subjects were consented to participate in the study. After baseline information was gathered from labs, it was determined that seven subjects did not meet the inclusion criteria. They were excluded from completing the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diabetic Type II Subjects</title>
          <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
        </group>
        <group group_id="P2">
          <title>Healthy Subjects</title>
          <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diabetic Type II Subjects</title>
          <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
        </group>
        <group group_id="B2">
          <title>Health Subjects</title>
          <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="5"/>
                    <measurement group_id="B2" value="45" spread="7"/>
                    <measurement group_id="B3" value="47" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Vitamin C in Type 2 Diabetic Patients.</title>
        <description>Concentrations of vitamin C were measured in the brains of type 2 Diabetic patients and healthy controls.</description>
        <time_frame>Pre-Vitamin C infusion</time_frame>
        <population>Determine cerebral concentrations of vitamin C. Data from one healthy subject were not usable due to subject's movement during MRI scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetic Type II Subjects</title>
            <description>Vitamin C level in the living brain</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects</title>
            <description>Vitamin C levels in the living brain.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Vitamin C in Type 2 Diabetic Patients.</title>
          <description>Concentrations of vitamin C were measured in the brains of type 2 Diabetic patients and healthy controls.</description>
          <population>Determine cerebral concentrations of vitamin C. Data from one healthy subject were not usable due to subject's movement during MRI scan.</population>
          <units>umol/g tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier</title>
        <description>Concentrations of vitamin C after IV infusion of Vitamin C were measured in the brains of patients with type 2 diabetes and healthy controls to examine whether the concentrations are different between two groups.</description>
        <time_frame>2 hour post infusion</time_frame>
        <population>Data from one healthy subject were not usable due to subject's movement during MRI scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetic Type II Subjects</title>
            <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects</title>
            <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
          </group>
        </group_list>
        <measure>
          <title>Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier</title>
          <description>Concentrations of vitamin C after IV infusion of Vitamin C were measured in the brains of patients with type 2 diabetes and healthy controls to examine whether the concentrations are different between two groups.</description>
          <population>Data from one healthy subject were not usable due to subject's movement during MRI scan.</population>
          <units>µmol/g tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diabetic Type II Subjects</title>
          <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
        </group>
        <group group_id="E2">
          <title>Healthy Subjects</title>
          <description>Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>In-Young Choi, Ph.D.</name_or_title>
      <organization>Univeristy of Kansas Medical Center</organization>
      <phone>913-588-0174</phone>
      <email>ichoi@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

